Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CARDINAL HEALTH, INC.

(CAH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cardinal Health : Voluntary Recall Announcement for Select MonojectTM Prefilled Saline Syringes

08/04/2021 | 08:06pm EDT
Voluntary Recall Announcement for Select MonojectTM Prefilled Saline Syringes
08/04/2021

In close coordination with the U.S. Food and Drug Administration (FDA), we have issued a voluntary recall for three SKUs in the Monoject™ Flush Prefilled Syringes (0.9% Sodium Chloride) portfolio, which are intended for use in flushing compatible intravenous tubing systems and indwelling intravascular access devices. The recall applies to all lots of the products distributed between July 2019 and July 2021.

SKU

Description

8881570121

12mL Syringe, 10 mL Saline Fill

8881570123

12mL Syringe, 3mL Saline Fill

8881570125

12mL Syringe, 5mL Saline Fill


Our Monoject™ 3mL syringe, 2.5mL Saline Fill is not affected by this recall. This item, SKU 8881570300, will be available for sale until inventory is depleted.

We are issuing the voluntary recall after learning that there is potential for the plunger to draw back after the air has been expelled and reintroduce air back into the syringe. If a clinician is not aware of air being reintroduced into the syringe, air could be inadvertently pushed into the vascular system creating the potential for an air embolism. At this time, Cardinal Health has not received any reports of patient harm or injury related to this issue.

These syringes are different from syringes used to administer COVID-19, flu and other vaccines.

Starting August 5, 2021, customers who may have received affected products will receive notification packets. Customers are instructed to:

  • review all inventory for affected products;
  • segregate all on-hand products;
  • communicate this notice to all clinical staff to ensure awareness of this product issue;
  • for the impacted Presource® kits, over labels will be provided to customers. The over labels can be adhered to the kits at the customer's facility;
  • return the acknowledgement form via fax or email;
  • and contact Customer Service to arrange for return and credits of any affected products.

Given the limited number of alternative prefilled saline syringe options, combined with ongoing supply, transportation and labor challenges, we anticipate that this recall may contribute to a market disruption of prefilled saline syringes. We are actively working to address the disruption and support customers' needs with locating alternative supply and we suggest that clinicians work with their facility to determine alternative fill methods.

As always, our top priority is the safety of patients, our customers and their healthcare workers. We are committed to helping ensure quality products for our customers and the patients they serve and understand and apologize for any disruption this recall causes in the healthcare system.

More Company News
08/04/2021

In close coordination with the U.S. Food and Drug Administration (FDA), we have issued a voluntary recall for three SKUs in the Monoject™ Flush Prefilled Syringes (0.9% Sodium Chloride)...

08/02/2021

Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis business to H&F. The sale price of...

07/30/2021

DUBLIN, Ohio-Cardinal Health WaveMark™ Supply Management & Workflow Solutions has released a whitepaper outlining how automated solutions for inventory management can mitigate supply chain...

07/22/2021

Change has been the one constant in nuclear medicine from the beginning, with the steady arrival of new radiopharmaceuticals, new technologies and an evolving regulatory environment. Today, as...

View all company news »

* Required Fields
* First Name
* Last Name
* Email

Disclaimer

Cardinal Health Inc. published this content on 04 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2021 00:05:06 UTC.


© Publicnow 2021
All news about CARDINAL HEALTH, INC.
10/15HISPANIC PHARMACISTS : Advancing health equity
PU
10/14VIRTUAL INTERVIEWING DURING THE PAND : How to seek your next role with peace of mind
PU
10/14CARDINAL HEALTH : OptiFreight Logistics to Ship Journey Biosciences' Diabetes Screening Te..
MT
10/14CARDINAL HEALTH : Journey Biosciences and Cardinal Health OptiFreight® Logistics Collabora..
PR
10/14Journey Biosciences and Cardinal Health, Inc. Optifreight Logistics Collaborate to Impr..
CI
10/12Cardinal Health, Inc. Provides Business Solutions for the Next Public Health Emergency
CI
10/06CARDINAL HEALTH : New Cardinal Health survey explores how rheumatologists are managing cur..
PR
10/04WALGREENS BOOTS ALLIANCE : Pharmacy chains failed to prevent opioid misuse, U.S. jury hear..
RE
10/04U.S. Supreme Court rejects challenge to New York tax on opioid companies
RE
09/30ENDO INTERNATIONAL : California judge questions counties' opioid case against drugmakers a..
RE
More news
Analyst Recommendations on CARDINAL HEALTH, INC.
More recommendations
Financials (USD)
Sales 2022 172 B - -
Net income 2022 1 298 M - -
Net Debt 2022 1 300 M - -
P/E ratio 2022 11,0x
Yield 2022 4,08%
Capitalization 13 921 M 13 921 M -
EV / Sales 2022 0,09x
EV / Sales 2023 0,08x
Nbr of Employees 46 827
Free-Float 88,4%
Chart CARDINAL HEALTH, INC.
Duration : Period :
Cardinal Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARDINAL HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 49,06 $
Average target price 56,85 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Michael C. Kaufmann Chief Executive Officer & Director
Jason M. Hollar Chief Financial Officer
Gregory B. Kenny Independent Non-Executive Chairman
Brian S. Rice Chief Information Officer & Executive VP
Jessica L. Mayer Chief Compliance & Legal Officer
Sector and Competitors